Navigation Links
NTRK1: A new oncogene and target in lung cancer
Date:6/3/2013

To the list of oncogenic drivers of lung cancer that includes ALK, EGFR, ROS1 and RET, results of a University of Colorado Cancer Center study presented at ASCO 2013 show that mutations in the gene NTRK1 cause a subset of lung cancers.

"We're reconceptualizing lung cancer as many, related diseases. And we need to learn to identify and treat each individually. We can treat the forms of the disease that depend on ALK and EGFR mutations. We're getting very close to treating lung cancers that depend on ROS1 and RET. And now we show another oncogenic driver of the disease that begs its own targeted treatment," says Robert C. Doebele, MD, PhD, investigator at the CU Cancer Center and assistant professor of medical oncology at the CU School of Medicine.

The group, in collaboration with Pasi A. Jnne, MD, PhD from the Dana-Farber Cancer Institute, started with lung cancer tumor samples from 36 "pan-negative" patients, meaning that no other driver oncogene had been identified. So if not EGFR, ALK and the like, what was driving the cancer? Doebele and colleagues took the question to Foundation Medicine (Cambridge, MA), which used targeted, next-gen sequencing to analyze the samples for possible mutations in a couple hundred potential oncogenes identified as drivers of other cancers. NTRK1 had been identified as a driver of thyroid cancer and so was included in the panel (though drug development had stalled due in part to the relative rarity of the thyroid disease). Sure enough, next-gen sequencing identified NTRK1 gene fusions as the potential driver in two of these samples.

Doebele and colleagues took the lead back to the CU labs, where Marileila Varella Garcia, PhD, developed a specific test for NTRK1 fusions based on fluorescence in situ hybridization (FISH), similar to what is used for ALK, ROS1 and RET fusions. This allowed the group to validate the finding of NRTK1 as a novel oncogene in these patient samples.

But the study went a step beyond identifying the oncogene. Doebele describes the relative ease with which genes that are improperly activated can be silenced "whether a drug is already is in clinical trials, or already approved for another cancer, or just sitting on the pharma shelf somewhere, many drugs exist that turn off these candidate genes," Doebele says.

In this case, Doebele describes "walking up the street to Array BioPharma (Boulder, CO), who happened to have several compounds specific for this gene."

The group showed that mutated NRTK1 genes in cells treated with drug candidates ARRY-772, -523, and -470 and others was effectively turned off.

"This is still preclinical work," Doebele says, "but it's the first and maybe even second and third! important steps toward picking off another subset of lung cancer with a treatment targeted to the disease's specific genetic weaknesses."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. New oncogene identified for breast cancer
2. Dietary glucose affects the levels of a powerful oncogene in mice
3. Hepatitis B virus promotes oncogenesis through microRNA modulation
4. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
5. RET rearrangement a new oncogene and potential target in lung cancer
6. Targeted therapeutics for colon cancer to be presented at AACR meeting
7. First targeted nanomedicine to enter human clinical studies
8. SMART heart eases heart ache, targets cardiac patients emotional well-being
9. Target set on cancer gene MCL1
10. Scientists tailor cell surface targeting system to hit organelle ZIP codes
11. IBN discovers human neural stem cells with tumor targeting ability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... today announced the publication of “Profiling protein expression in circulating tumor cells using ... publication describes the use of the Vortex technology to capture CTCs ...
(Date:3/22/2017)... ... March 22, 2017 , ... Cosmetic Town, an online ... of its companion print magazine. The new magazine, scheduled for release in mid-April, ... provided by board-certified doctors from across the country. , According to the senior ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... Bay Area providing insurance assistance, financial planning, and related services to residents of ... International to promote awareness of threatened species and wild lands. , Endangered Species ...
(Date:3/22/2017)... Jacksonville, FL (PRWEB) , ... March 22, 2017 ... ... (ASPC) convened experts to create a PCSK9 inhibitor prior authorization (PA) form for ... high cholesterol. It is one of the helpful tools published as part of ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... frustrating and this tool bypasses that. Healthcare facilities across the country are ... to offer their clients and hospitals, across the country, an efficient and quick ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... March 22, 2017 New Jersey,s ... of patient harm and saved $641 million in healthcare ... in a national quality improvement program. ... for Patients-New Jersey, part of a national initiative from ... selected the New Jersey Hospital Association and its affiliate, ...
(Date:3/22/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Pharmaceutical Packaging Market is poised to ... to reach approximately $129.81 billion by 2025. This industry ... segments on global as well as regional levels presented in the ...
(Date:3/22/2017)... A new independent study demonstrates that ... ultraviolet-C (UV-C) disinfection solution of choice for combating ... Published in the March issue of the ... peer-reviewed study of UV-C disinfection systems detailed the ... and Rochester General Hospital. According to the study, ...
Breaking Medicine Technology: